Prescription medicine
Conjugated estrogens and medroxyprogesterone Brand names: Premphase
Conjugated estrogens and medroxyprogesterone (Premphase) is a prescription medicine. No generic is listed; pharmacies paid $8.68 per Premphase 0.625-5 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: conjugated estrogens and medroxyprogesterone labels on DailyMed; every conjugated estrogens and medroxyprogesterone label on DailyMed.
Highlights of the record
no current FDA label; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
The label in openFDA carries no indications section.
Forms and strengths
Kit.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $8.68 per tablet Premphase 0.625-5 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 23,464 through July 30, 2026
Is there a generic for conjugated estrogens and medroxyprogesterone (Premphase)?
No generic conjugated estrogens and medroxyprogesterone is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for conjugated estrogens and medroxyprogesterone (Premphase)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $8.68 per Premphase 0.625-5 mg tablet, up 2% from $8.48 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Premphase 0.625-5 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Premphase 0.625-5 mg tablet | Brand | $8.68 per tablet | $260.44 | +2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for conjugated estrogens and medroxyprogesterone?
The FDA Adverse Event Reporting System holds 23,464 reports that list conjugated estrogens and medroxyprogesterone among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 647 are coded as a death and 2,758 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other estrogens
- the pharmacologic class, with prices and generics
- Conjugated estrogens and medroxyprogesterone side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other